| Name | (R)-Terazosin |
| Description | (R)-Terazosin is an active R-enantiomer of Terazosin and a potent antagonist of α1-adrenoceptor [(α1a, α1b, and α1d-adrenoceptor] with Ki values of 6.51 nM, 1.01 nM, and 1.97 nM, respectively). |
| In vitro | (R)-Terazosin exhibits low affinity for α2a, α2B, and α2c-adrenoceptors (Ki of 3.85 μM, 0.33 μM, and 0.37 μM, respectively). It may serve as a useful probe for exploring the functional roles of adrenoceptor subtypes in various tissues. |
| In vivo | (R)-Terazosin demonstrates antagonism at rat atrial α2B receptor (pEC30: 5.69) and at rat vas deferens α1A and α2A receptors (pA2: 7.5 and 5.31, respectively). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 55 mg/mL (141.96 mM), Sonication is recommended.
|
| Keywords | Terazosin | (R)-Terazosin | α1-adrenoceptor | affinity | inhibit | subtypes | prove | Adrenergic Receptor | (R)Terazosin | Inhibitor | (R) Terazosin | Low | α2-adrenoceptor | Beta Receptor |
| Inhibitors Related | Octopamine hydrochloride | Trazodone hydrochloride | Mianserin hydrochloride |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
